BIIB: Biogen Inc Analyst Median Target
Biogen Inc. (BIIB) is a recognized leader in neurobiology, possessing unique expertise in developing highly complex brain medications and patent-protected technologies. The company's revenues are based on the sale of cutting-edge treatments for Alzheimer's, SMA, and multiple sclerosis. The market valuation dynamics of the asset at the level of 271.47 are available below. Meanwhile, the production of key substances remains in-house, while testing is delegated to external laboratories.
Analytical breakdowns for Biogen Corp (BIIB)
- current price and projected stock value:
- market capitalization information:
- company book value details:
- debt obligations and liquidity statistics:
- net income and valuation ratios data:
BIIB - Net Profit|Expected Profit Biogen Inc.|BIIB - P/E Multiple|Market Cap to Projected Earnings Biogen Inc|BIIB - Price/Earnings to Growth Ratio|Company Value to EBITDA Biogen Corp|BIIB - Operating profit EBITDA|Net earnings per share for the trailing year Biogen|BIIB - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months biogen.com|BIIB - Earnings per share growth in current year|Projected earnings per share growth rate for next year Biogen Inc.
Summary company analytics:BIIB biogen.com
A consensus forecast, which aggregates expert fair value estimates based on discounted cash flows and market premiums, is critical for selecting assets with a high margin of safety. In the case of Biogen Inc. (BIIB), this indicator reflects the monetization of patent protection and stable demand for rare disease therapies, as clearly evidenced by the analyst consensus chart for the stock.
Competitors of Biogen Inc.
Price Target Chart NBIX (neurocrine.com)|Analyst Consensus Forecast RGC (Regencell Bioscience Holdings Limited)|Analyst Median Target Axsome (AXSM)|ACADIA Pharmaceuticals Inc - Analyst Consensus Forecast|Analyst Median Target Xenon Corp XENE|VKTX: Analyst Consensus Forecast|SUPN (supernus.com) - Price Target Chart|Price Target Chart Catalyst Pharmaceuticals, Inc.|Broker Consensus Forecast DNLI (Denali)|Analyst Consensus Forecast HRMY|BHVN - Average Forecast Price|Amylyx Pharmaceuticals - Consensus Target|Analyst Consensus Forecast trevitherapeutics.com TRVI|PRAX - Price Target Chart|Fair Value Consensus AVXL (Anavex)|CeriBell Corp (CBLL) - Price Target Chart|Average Forecast Price Prothena Corporation plc (PRTA)|ALEC (Alector Inc.) - Analyst Consensus Forecast|Price Target Chart ANNX|Analyst Consensus Forecast OMER|Analyst Median Target Neurogene Inc|Price Target Chart AC Immune Corp ACIU|Voyager Corp (VYGR) - Average Forecast Price|Neumora Therapeutics - Analyst Consensus Forecast|Analyst Target Range scilexholding.com (SCLX)|TVGN: Analyst Consensus Forecast|Average Forecast Price Alpha Cognition Inc. (ACOG)|Price Target Chart Cognition Therapeutics|Broker Consensus Forecast IKT (Inhibikase Pharma)|Consensus Target SAVA (Cassava Sciences, Inc.)|ASRT (assertiotx.com) - Fair Value Consensus|Analyst Consensus Forecast COYA (Coya Therapeutics)|Analyst Median Target VistaGen Therapeutics, Inc. (VTGN)|OVID - Price Target Chart|ABOS (Acumen Pharmaceuticals, Inc) - Broker Consensus Forecast|CRVO: Analyst Consensus Forecast|Consensus Target Alterity Therapeutics Limited|Consensus Target CLNN|PepGen Corp (PEPG) - Analyst Median Target|Analyst Consensus Forecast JUNS|Price Target Chart RLMD (Relmada Corp)|Analyst Consensus Forecast ANVS (Annovis Bio, Inc.)|Analyst Median Target Grace Therapeutics Inc (GRCE)|Firefly Neuroscience - Analyst Consensus Forecast|Analyst Median Target Klotho Neurosciences Inc KLTO|NRSN: Analyst Consensus Forecast|RVPH (Reviva Pharmaceuticals, Inc.) - Price Target Chart|Price Target Chart MetaVia Inc.|Broker Consensus Forecast NRXS (neuraxis.com)|Analyst Consensus Forecast HSDT|PASG - Average Forecast Price|Neuphoria Therapeutics - Consensus Target|Analyst Consensus Forecast Minerva NERV|ATHA - Price Target Chart|Fair Value Consensus ADXN (addextherapeutics.com)|alzamend.com (ALZN) - Price Target Chart|Average Forecast Price Cyclerion Therapeutics, Inc. (CYCN)|PTIX (Protagenic Therapeutics Inc.) - Analyst Consensus Forecast|Price Target Chart KTTA|Analyst Consensus Forecast CRGT|Analyst Median Target avenuetx.com|Price Target Chart BrainStorm Cell Therapeutics BCLI|Cara Therapeutics Inc. (CARA) - Average Forecast Price|Chromocell Therapeutics Corporation - Analyst Consensus Forecast|Analyst Target Range Eliem Therapeutics (ELYM)|ITCI: Analyst Consensus Forecast|Average Forecast Price longboardpharma.com (LBPH)|Price Target Chart Marinus Pharmaceuticals, Inc.|Broker Consensus Forecast NKGN (NKGen Biotech Inc)|Consensus Target NRBO (NeuroBo)|SAGE (Sage Therapeutics Inc) - Fair Value Consensus|Analyst Consensus Forecast SNPX (Synaptogenix, Inc.)|Analyst Median Target trevena.com (TRVN)|VIGL - Price Target Chart|WENA (Anew Medical Inc.) - Broker Consensus Forecast|CERE: Analyst Consensus Forecast
